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Abstract
Aim—To develop a nomogram from clinical and computed tomography (CT) data for pre-
treatment identification of indolent renal cortical tumors.
Patients and Methods—1,201 consecutive patients underwent dedicated contrast-enhanced CT 
prior to nephrectomy for a renal cortical tumor between January 2000 and July 2011. Two 
radiologists evaluated all tumors on CT for size, necrosis, calcification, contour, renal vein 
invasion, collecting system invasion, contact with renal sinus fat, multicystic tumor architecture, 
nodular enhancement, and the degree of nephrographic phase enhancement. CT and clinical 
predictors (gender, BMI, age) were incorporated into the nomogram. We employed multivariable 
logistic regression analysis to predict tumor type and internally validated the final model using the 
data from reader 1. External validation was performed by using all data from reader 2. We applied 
Wilcoxon rank sum test and Fisher's exact test to investigate for differences in tumor size, BMI, 
age, and differences in CT imaging features between patients with aggressive and those with 
indolent tumors.
Results—63.6% (764/1’201) of patients had clear-cell or other aggressive non-clear-cell RCC 
(i.e. papillary RCC type 2, unclassified RCC) and 36.4% (437/1’201) had indolent renal cortical 
tumors (i.e. papillary RCC type 1, chromophobe RCC, angiomyolipoma, or oncocytoma). On CT, 
indolent tumors were significantly smaller (p<0.001) than aggressive tumors and significantly 
associated with well-defined tumor contours (p<0.001). Aggressive RCC were significantly 
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associated with necrosis, calcification, renal vein invasion, collecting system invasion, contact with 
renal sinus fat, multicystic tumor architecture, and nodular enhancement (all, p<0.001). The 
nomogram's C-index was 0.823 after internal and 0.829 after external validation.
Concluding Statement—We present a nomogram based on 1,201 patients combining CT 
features with clinical data for the prediction of indolent renal cortical tumors. When externally 
validated, this nomogram resulted in a concordance index of 0.829.
Keywords
CT; Computed Tomography; Renal Cell Carcinoma; RCC; Clear Cell; Chromophobe; Papillary; 
Oncocytoma; Angiomyolipoma; Nomogram
Introduction
Renal cell carcinoma (RCC) comprises a heterogeneous group of renal epithelial cancers, 
which may be classified into clear cell, papillary, chromophobe and other, either unclassified 
or less common subtypes.[1, 2] Among the more common subtypes, clear cell RCC has the 
worst prognosis, while papillary and chromophobe RCC may be considered indolent tumors, 
because they remain localized and are therefore often curable.[3] Aside from malignant 
renal cortical tumors, the benign oncocytoma and lipid-poor angiomyolipoma frequently 
mimic clear cell RCC on medical imaging and thus substantially contribute to the fact that 
about 10%-20% of renal cortical tumors resected because RCC is initially suspected prove 
to be benign.[4]
Given these differences in aggressiveness of histological subtypes of RCC and the tendency 
of oncocytomas and lipid-poor angiomyolipomas to mimic clear cell RCC, improved 
medical imaging strategies are needed for identifying indolent renal cortical tumors 
preoperatively, so that unnecessary invasive biopsy and/or treatment can be avoided in the 
future. A number of recent studies investigated the ability of computed tomography (CT), 
the most commonly used imaging modality for patients with renal cortical tumors, to 
differentiate not only between subtypes of RCC, but also between RCC and oncocytoma or 
the more prevalent angiomyolipoma.[5-9] A common finding of most of the studies was that 
the degree of early enhancement during the corticomedullary phase was largest for clear cell 
RCC followed by oncocytoma, chromophobe RCC, and papillary RCC [10]. However, since 
both clear cell RCC and oncocytoma demonstrate peak enhancement during the 
corticomedullary phase, these two entities may not be reliably differentiated by the exclusive 
use of contrast enhancement analyses.
Today, nomograms are often used to assess the level of risk posed by a patient's cancer. Yet 
to date, no nomograms that incorporate morphologic imaging features (other than tumor 
size) have been developed for distinguishing clear-cell or unclassified RCC from more 
indolent or benign types of renal cortical tumors.
Therefore, the purpose of this study was to develop a nomogram that combines clinical data 
with CT features for the non-invasive, pretreatment identification of indolent, non-clear-cell 
renal cortical tumors.
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Material (Patients) and Methods
Patients
Our institutional review board approved this retrospective HIPAA-compliant study, and 
waived the requirement for informed consent. Patients were included in the study upon 
fulfilment of all of the following criteria:
(a) Nephrectomy performed at our institution (a tertiary care cancer center) between 
January 2000 and July 2011 for localized clear cell RCC, localized 
chromophobe RCC, localized papillary RCC types 1 and 2, localized 
unclassified RCC, oncocytoma, or angiomyolipoma.
(b) Pre-operative contrast-enhanced CT of the abdomen and pelvis performed at our 
institution using a dedicated kidney CT protocol and available in DICOM format 
through our institution's PACS.
(c) Availability of clinical information (i.e., gender, age, body mass index [BMI], 
clinical presentation [i.e. symptomatic or asymptomatic]) as well as 
histopathology reports indicating the histopathological tumor type through our 
institution's electronic medical records system.
As shown in the patient selection flowchart (Figure 1), a total of 1,201 patients were eligible 
for inclusion in this study.
CT Image Acquisition & Analysis
All patients underwent multiphasic contrast-enhanced CT imaging prior to nephrectomy 
using either 16- or 64- detector row CT scanners (General Electric Medical Systems, 
Milwaukee, USA) at a constant tube voltage setting of 120 kV. All CT studies consisted of 
non-enhanced imaging of the abdomen as well as contrast-enhanced imaging during the 
nephrographic (delay, 90 sec) and urographic (delay, 3 min) phases after the application of 
150 mL of iodinated contrast agent (Omnipaque 300, GE Healthcare) at a constant flow rate 
of 3.5 mL/sec. In patients with creatinine levels above 1.3, the amount of contrast agent was 
reduced to 100 mL. Reconstruction slice thickness was 2.5 mm for all CT studies. In 
patients who had more than one tumor (8.2% [99/1’201]), the largest lesion was chosen for 
analysis.
Without knowledge of neither histopathological nor clinical information, two board-certified 
radiologists performed all image analyses using commercially available PACS software 
(Centricity, General Electric Medical Systems; Milwaukee, USA). Both radiologists 
independently assessed all images for the following features:
(a) The largest tumor diameter on the transverse CT image during the 
nephrographic phase;
(b) The presence of necrosis (a tumor was deemed necrotic if ill-defined, hypodense 
areas of the tumor did not enhance at all during the nephrographic and 
urographic phases);
(c) The presence of calcifications within the tumor.
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(d) The nature of the tumor's contour, recorded as either ill-defined or well-defined 
(a tumor contour was deemed ill-defined if the tumor was not clearly delineated 
from all adjacent anatomical structures on all transverse imaging planes during 
the nephrographic phase);
(e) Evidence of venous invasion, defined as a filling defect caused by tumor 
extension into the branches of the renal vein on nephrographic phase images;
(f) Evidence of collecting system invasion, defined as a filling defect within the 
collecting system on urographic phase images;
(g) Evidence of tumor contact with renal sinus fat, defined as direct contact between 
the tumor and the adipose tissue of the renal sinus;
(h) Evidence of multicystic tumor architecture;
(i) Evidence of heterogeneous (i.e. peripheral-nodular) enhancement during the 
nephrographic phase.
Figure 2 illustrates examples of all features.
In addition, one reader measured the Hounsfield Unit density of each tumor's most solid 
component on unenhanced and nephrographic-phase, contrast-enhanced CT images as 
baseline parameters to calculate the degree of nephrographic phase enhancement.
Statistical Analysis
The objective of this project was to develop a pre-operative model for the prediction of the 
following indolent renal cortical tumor types: papillary RCC type 1, chromophobe RCC, 
oncocytoma, and angiomyolipoma. On the contrary, we classified these tumor types as 
aggressive: clear cell RCC, unclassified RCC, and papillary RCC type 2. From here on we 
refer to the above mentioned groups as “indolent tumors” and “aggressive tumors”. For the 
calculation of the predictive model, we combined clinical predictors (i.e. gender, age, and 
BMI), and predictors derived from CT imaging (i.e., tumor size, necrosis, calcification, 
tumor contour, renal vein invasion, collecting system invasion, tumor contact with renal 
sinus fat, multicystic tumor architecture, nodular enhancement pattern, and the degree of 
nephrographic phase enhancement).
Multivariable logistic regression analysis was employed to predict tumor type. All clinical 
and CT variables, as assessed by reader 1, were included in an initial model. A step-down 
method based on the concordance index (C-index) was used to select a subset of the 
predictors to achieve a relatively parsimonious model with the maximum C-index, for the 
final model. The final model was internally validated using data from reader 1. External 
validation was performed by using all data from reader 2. The C-index was used as an 
indicator to present predictive accuracy, which is identical to the area under the receiver 
operating characteristic (ROC) curve. The C-index ranges from 0.5 (no predictive power) to 
1 (perfect prediction). Calibration of the nomogram was assessed graphically by smoothing 
a scatter plot of the predicted probabilities and the observed outcomes. The plot illustrates 
how far the prediction is from the actual tumor type (the closer the line is to the 45-degree 
line, the better the nomogram predicts).
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Wilcoxon rank sum test was applied to investigate for differences in tumor size, body mass 
index, age and the degree of nephrographic phase enhancement between patients with 
aggressive and those with indolent tumors. Fisher's exact test was applied to investigate for 
differences between aggressive and indolent tumors with respect to the distribution of 
necrosis, calcifications, tumor contour, renal vein invasion, collecting system invasion, 
tumor contact with renal sinus fat, presence of multicystic tumor architecture, and nodular 
enhancement.
Results
The patients’ clinical and CT Imaging characteristics are summarized in Table 1. A 
multivariable logistic regression model was developed to predict binary outcome of tumor 
type (aggressive versus indolent tumors). Ten out of fifteen predictors were included in the 
final model. Clinical presentation was dropped, because it reduced the concordance index. 
The predictors included in the final model were: age, gender, BMI, CT necrosis, CT 
calcifications, CT tumor contour, CT renal vein invasion, CT collecting system invasion, CT 
presence of multicystic tumor architecture, CT tumor contact with renal sinus fat, CT 
nodular enhancement, CT tumor size, and CT nephrographic enhancement. Interreader 
agreement for all features was excellent (Table 2). While the results of reader 1 were used to 
construct the nomogram, the results of reader 2 served to validate the nomogram.
Patients with indolent tumors, when compared to those with aggressive tumors, had a 
significantly lower BMI (28.7±5.5 vs. 30.2±6.2; p=0.0001). No significant differences were 
found for age (p=0.1311) and gender (p=0.0545) between patients with indolent and 
aggressive tumors. Indolent tumors were significantly smaller (4.0±2.5 cm vs. 4.4±2.6 cm; 
p=0.0001) than aggressive tumors. Regarding the predictors derived from CT imaging, ill-
defined tumor contour, presence of necrosis and calcifications, evidence of renal vein 
invasion, evidence of collecting system invasion, contact with renal sinus fat, presence of 
multicystic tumor architecture, nodular enhancement were significantly associated with 
aggressive tumors (all, p<0.001; Table 3). Nephrographic phase enhancement was 
significantly higher in aggressive tumors when compared to indolent tumors (289.8%
±169.8% vs. 202.5±154.6%; p<0.0001).
The graphic nomogram derived from the final regression model is presented in Figure 3. 
The C-index based on internal validation of the nomogram was 0.823, and 0.829 for external 
validation. The calibration plot is presented in Figure 4, odds ratios in Table 4.
Discussion
We developed a nomogram for the pre-treatment identification of indolent, non-clear cell 
renal cortical tumors based on clinical and CT imaging data derived from 1,201 patients. 
When externally validated, the nomogram led to a concordance index of 0.829.
Nomograms have previously been designed to predict patient survival based on data 
acquired before or after treatment of renal tumors. Lane et al. developed a pre-treatment 
nomogram that incorporated clinical data with tumor size on CT to predict the presence of 
malignant tumors in patients with small renal masses. This nomogram was designed using 
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data from 862 patients with solid renal lesions 7 cm or less in size. When internally 
validated, the nomogram had a bootstrap-corrected C-index of 0.644. The nomogram 
resulted in an even lower C-index of 0.557 for the prediction of potentially aggressive 
histology.[11] Our nomogram, which incorporated fewer clinical variables but a larger 
number of CT imaging features and focused specifically on the identification of indolent 
tumors, resulted in a higher C-index of 0.829.
Raj et al. developed a pre-operative nomogram for the prediction of metastatic recurrence at 
12 years based on data from 2517 patients [12]. This nomogram, which resulted in a C-index 
of 0.8, included gender, clinical presentation (i.e. incidental, localized, systemic), as well as 
tumor size, lymphadenopathy and evidence of necrosis on imaging. Our nomogram (which 
aimed to predict tumor histology rather than recurrence) included a larger number of 
predictors from CT, namely, tumor size, tumor contour (either ill- or well-defined), evidence 
of renal vein invasion, evidence of tumor contact with renal sinus fat, presence multicystic 
tumor architecture, and evidence of heterogeneous enhancement during the nephrographic 
phase – a feature that may be understood to imply the presence of necrosis within a tumor.
We included the definition of a tumor's contour because we hypothesized that indolent 
tumors would display clearer delineation towards the normal kidney parenchyma than would 
aggressive tumors; in keeping with this expectation, we discovered that aggressive tumors 
displayed ill-defined contours significantly more often than did indolent tumors (Table 3). 
We also found, as we had expected, that renal vein invasion was significantly more common 
among aggressive tumors than among indolent tumors (Table 3). Therefore, the presence of 
renal vein invasion on CT imaging may be considered a strong predictor for aggressive 
tumor. In addition, we included direct contact between the renal cortical tumor and the renal 
sinus fat because this feature is known as a surrogate marker for invasion of muscular 
venous branches of the renal vein, and therefore stage T3a.[13, 14] Interestingly, we found 
that contact between renal cortical tumors and renal sinus fat was significantly more 
common among aggressive tumors than among indolent tumors. However, size may have 
been a confounding factor influencing this finding, given that, if a renal cortical tumor grows 
large, it will eventually establish contact with the renal sinus fat, and in our study, aggressive 
tumors were significantly larger than indolent tumors (4.4±2.6 cm vs. 4.0±2.5 cm; 
p=0.0001). However, it has previously been shown that small renal cortical tumors clearly 
separated from the renal sinus fat were significantly less likely to present as stage T3a 
during histopathological analysis.[13, 14]
In our study, aggressive tumors demonstrated a peripheral nodular enhancement pattern 
during the nephrographic phase significantly more often than did indolent tumors. This 
finding may be explained by an observation from a prior study, which indicated that nodular 
enhancement patterns were related to mutations of the Von Hippel Lindau (VHL) gene. The 
VHL gene is a trigger mutation in clear cell RCC and leads to an up-regulation of hypoxia-
inducing factors, thereby resulting in increased angiogenesis, which can be identified on 
contrast-enhanced CT imaging.[15]
We also found that patients with aggressive tumors had a significantly higher body mass 
index. This rather interesting finding was in line with the results of a prior study by 
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Lowrance et al., who demonstrated that among patients with renal cortical tumors, obesity 
was associated with an elevated risk of clear cell RCC [16].
Our study had the following limitations: First, we included CT exams acquired on different 
CT scanners. However, our analysis was retrospective, and we aimed to keep the sample size 
as large as possible for the construction of the nomogram. Moreover, we exclusively 
included CT exams that had been performed at our institution using a dedicated renal mass 
protocol. Second, histopathology specimens were not re-analysed by a pathologist for this 
study, although all our nephrectomies, as a routine, are signed out by a dedicated 
genitourinary pathologist only. Third, the amount of contrast material applied in each patient 
was not weight corrected; therefore, CT features associated with enhancement could have 
been affected by the different, non-weight-adapted doses of contrast material. Fourth, as 
long as they remain small, most angiomyolipomas that can be identified as such clearly on 
imaging are followed with imaging rather than surgically resected. Therefore, 
angiomyolipomas in this study were either large or highly atypical, meaning that they did 
not demonstrate macroscopic fat on CT imaging.
In conclusion, we designed an easy-to-use nomogram that appears to be reasonably accurate 
for the pre-treatment prediction of indolent, non-clear cell renal cortical tumors. This 
nomogram in its current form does not have the power to replace biopsy but may contribute 
to decision making processes in the management of patients with renal cortical tumors.
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Highlights
• Our nomogram contains clinical and imaging derived data.
• We aimed to differentiate aggressive from indolent types of renal cortical 
tumors.
• The nomogram resulted in an externally validated C-index of 0.829.
• Aggressive renal cancer was more likely to be in contact with renal sinus fat.
• Indolent renal tumors were more likely homogeneous in enhancement on 
imaging.
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Figure 1. 
Patient selection flowchart.
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Figure 2. 
CT imaging features as assessed by both readers: A, necrosis; B, calcifications; C, Ill-
defined tumor margin; D, well-defined tumor margin; E, renal vein invasion; F, collecting 
system invasion; G, contact with the renal sinus; H, evidence of multicystic tumor 
architecture; I, nodular enhancement pattern; and J, solid enhancement pattern.
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Figure 3. 
Nomogram for predicting the probability of indolent renal cortical tumor histology. Points 
were assigned by drawing a straight line from the appropriate spot on the level of each 
predictor up to the “Points” level; a line was then drawn straight down from the appropriate 
spot on the “Total points” level to determine the corresponding predicted probability of 
indolent tumor histology.
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Figure 4. 
Nomogram calibration plot. The dots close to the top illustrate the distribution of predicted 
probabilities for indolent tumors.
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Table 1
Clinical data & Parameters derived from CT
Total Number of Patients N=1'201
Gender
Male 62.4% (749/1'201)
Female 37.6% (452/1'201)
BMI (mean ± SD, range) 29.7 ± 6 (9.6-61.8)
Age (mean ± SD, range; in years) 60.4 ± 11.9 (22-95)
Clinical Presentation
Symptomatic 17.7% (213/1'201)
Asymptomatic 82.3% (988/1'201)
Histopathological Tumor Type
Clear cell renal cell carcinoma 56% (673/1'201)
Papillary renal cell carcinoma
Type 1 12.8% (154/1'201)
Type 2 2.3% (28/1'201)
Chromophobe renal cell carcinoma 12.3% (148/1'201)
Oncocytoma 8.8% (105/1'201)
Unclassified renal cell carcinomas 5.3% (63/1'201)
Angiomyolipoma 2.5% (30/1'201)
Type of Nephrectomy
Partial 75.4% (906/1'201)
Radical 24.6% (295/1'201)
CT Predictors Reader 1 Reader 2
Tumor Size (mean ± SD, range, in cm) 4.3 ± 2.6 (0.9-21.5) 4.3 ± 2.6 (0.9-21.5)
Necrosis 65% (781/1'201) 64.7% (777/1'201)
Calcification 17.6% (211/1'201) 17.9% (215/1'201)
Tumor Contour
Ill-defined 44.5% (535/1'201) 49.4% (593/1'201)
Well-defined 55.5% (666/1'201) 50.6% (608/1'201)
Renal Vein Invasion 6.7% (80/1'201) 5% (60/1'201)
Collecting System Invasion 9.7% (116/1'201) 6.6% (79/1'201)
Tumor Contact with Renal Sinus Fat 65.8% (790/1'201) 66.7% (801/1'201)
Multicystic Tumor Architecture 13% (156/1'201) 11.5% (138/1'201)
Nodular Enhancement 45.3% (544/1'201) 43.7% (525/1'201)
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Table 2
Interreader Agreements
CT Predictor Kappa Value Lower 95% CI Upper 95% CI
Necrosis 0.982 0.97 0.993
Calcifications 0.937 0.911 0.963
Contour 0.900 0.875 0.925
Renal Vein Invasion 0.636 0.536 0.737
Collecting System Invasion 0.794 0.729 0.859
Tumor Contact to Renal Sinus Fat 0.957 0.94 0.975
Multicystic 0.923 0.889 0.956
Nodular Enhancement 0.961 0.946 0.977
CI = Confidence Interval
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Table 3
Comparison of clinical and CT imaging predictors in clear cell and non-clear cell tumors
Predictors
Indolent Tumor Type
p *
Yes No
Body Mass Index (mean±SD; range) 28.7±5.5 (9.6-51.2) 30.2±6.2 (10-61.8) 0.0001
Age (mean±SD; range) 61±11.9 (22-95) 60±11.9 (32-85) 0.1311
Gender
Male 58.8% (257/437) 64.4% (492/764)
0.0545
Female 41.2% (180/437) 35.6% (272/764)
CT Tumor Size (mean±SD; range; in cm) 4±2.5 (0.9-16.7) 4.4±2.6 (1-21.5) 0.0001
CT Nephrographic Enhancement (mean±SD; range) 202.5±154.6 (−33.3-706.2) 289.8±169.8 (−43.8-754.5) <0.0001
Necrosis
no 63.2% (276/437) 81.2% (620/764)
<0.0001
yes 36.8% (161/437) 18.8% (144/764)
Calcifications
no 86.7% (379/437) 80% (611/764)
0.0031
yes 13.3% (58/437) 20% (153/764)
Tumor Contour
Well-Defined 70.3% (307/437) 47% (359/764)
<0.0001
Ill-Defined 29.7% (130/437) 53% (405/764)
Renal Vein Invasion
no 98.2% (429/437) 90.6% (692/764)
<0.0001
yes 1.8% (8/437) 9.4% (72/764)
Collecting System Invasion
no 1.6% (7/437) 85.7% (655/764)
<0.0001
yes 98.4% (430/437) 14.3% (109/764)
Tumor Contact With Renal Sinus Fat
no 48.5% (212/437) 26% (199/764)
<0.0001
yes 51.5% (225/437) 74% (565/764)
Multicystic tumor architecture
no 95.9% (419/437) 81.9% (626/764)
<0.0001
yes 4.1% (18/437) 18.1% (138/764)
Nodular Enhancement Pattern
no 75.1% (328/437) 43.1% (329/764)
<0.0001
yes 24.9% (109/437) 56.9% (435/764)
*derived from Wilcoxon rank sum test & Fisher's exact test; SD = standard deviation;
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Table 4
Odds ratios for the prediction of indolent renal cortical tumors – final selection of predictors.
Predictors Odds Ratio Lower 0.95 Upper 0.95
Body Mass Index 0.6174 0.5185 0.7351
CT Tumor Size 1.6071 1.3402 1.927
CT Necrosis 0.253 0.1815 0.3527
CT Contour 0.5986 0.4411 0.8124
CT Renal Vein Invasion 0.4546 0.1833 1.1272
CT Collecting System Invasion 0.1516 0.061 0.3765
CT Tumor Contact to Renal Sinus Fat 0.5297 0.382 0.7344
CT Multicystic Tumor Architecture 0.2942 0.1665 0.5198
CT Nodular Enhancement 0.5384 0.3815 0.7599
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